Sumitomo, Protez Conclude Licensing Agreement for SMP-601

Sumitomo Pharmaceuticals announced that it has signed a licensing agreement with Protez Pharmaceuticals for SMP-601, Sumitomo's proprietary antibiotic candidate. Founded in 2003 with the aid of BTG, Protez Pharmaceuticals is a U.S. venture company engaged in developing innovative antibiotics to combat drug-resistant and other difficult-to-treat infections.

()a href="http://www.japancorp.net/Article.Asp?Art_ID=10103" target="_blank">Japan Corporate News Network